Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Interest & Investment Income: 2023-2025

Historic Interest & Investment Income for Aclaris Therapeutics (ACRS) over the last 2 years, with Sep 2025 value amounting to $1.8 million.

  • Aclaris Therapeutics' Interest & Investment Income fell 8.64% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year increase of 0.85%. This contributed to the annual value of $8.0 million for FY2024, which is 6.53% down from last year.
  • As of Q3 2025, Aclaris Therapeutics' Interest & Investment Income stood at $1.8 million, which was down 9.86% from $2.0 million recorded in Q2 2025.
  • Aclaris Therapeutics' Interest & Investment Income's 5-year high stood at $2.3 million during Q3 2023, with a 5-year trough of $1.8 million in Q3 2025.
  • Over the past 3 years, Aclaris Therapeutics' median Interest & Investment Income value was $2.0 million (recorded in 2025), while the average stood at $2.1 million.
  • As far as peak fluctuations go, Aclaris Therapeutics' Interest & Investment Income decreased by 14.03% in 2024, and later rose by 8.84% in 2025.
  • Quarterly analysis of 3 years shows Aclaris Therapeutics' Interest & Investment Income stood at $2.2 million in 2023, then dropped by 3.93% to $2.1 million in 2024, then dropped by 8.64% to $1.8 million in 2025.
  • Its last three reported values are $1.8 million in Q3 2025, $2.0 million for Q2 2025, and $2.2 million during Q1 2025.